AmVac AGAmVac AG is a biopharmaceutical company in Switzerland cialis 100 mg.

AmVac AGAmVac AG is a biopharmaceutical company in Switzerland cialis 100 mg . The company focuses on the vaccine market with its above-average growth rates. There are two therapeutic vaccines in the pipeline. Soon in the fields of gynecology and urology Further innovative vaccines and technologies are being developed. The renowned market research company Frost & Sullivan awarded AmVac AG. The coveted ‘Enabling Technology of the Year Award’in 2007.

Until: the development of a spray flu vaccine by the lack of a safe adjuvant capable of improving hampered strong mucosal immunity. AmVac has exclusive rights to the MALP-2 , the Professor developed at the Helmholtz Centre for Infection Research in Braunschweig purchased world for all infectious diseases. These synthetic, well-tolerated class of adjuvants acts as Toll-like receptor agonist in activation of cells of the immune system and in central locations in mediating the immune response. Animal models have demonstrated strong antibody and cellular responses. Preliminary results on mice have shown that the pandemic H5N1 influenza vaccine combined with MALP-2, influenza – specific antibodies induces after intranasal immunization. The first clinical studies on the H5N1 vaccine will begin in 2009, during the implementation of the planned combination with the adjuvant for clinical use in 2011.

Additionally, in the gefitinib group, lungs, which in the mutation of – a negative subgroup was shorter than the out of which mutations-positive group . There was no distinction between them two subsets in the in the chemotherapy group. – Gefitinib not improved overall survival than standard chemotherapy, Jin S. Manager to the National Cancer Centre Korea told Goyang, however, proposes a very promising The outcome the together with high level of overall response and improved toxicity my Profile that gefitinib might be a adequate first-line therapy the does not – Designated Smoking cancer patients to be. .